China’s retaliatory tariffs on US could mean more headwinds for drugmakersnews2025-04-04T17:25:01+00:00April 4th, 2025|Endpoints News|
F-star management takes company private, two years after $161M cash exit to Sino’s invoXnews2025-04-04T02:01:44+00:00April 4th, 2025|Endpoints News|
WuXi Biologics’ licensing deals help offset Biosecure threat in the USnews2025-03-25T15:11:03+00:00March 25th, 2025|Endpoints News|
Merck and Hengrui strike $2B deal for Lipoprotein(a) drugnews2025-03-25T10:30:41+00:00March 25th, 2025|Endpoints News|
AstraZeneca puts $2.5B toward first vaccine factory and second R&D site in Chinanews2025-03-21T15:24:18+00:00March 21st, 2025|Endpoints News|
AstraZeneca broadens presence in China, promising $8B+ to Harbour and Syneronnews2025-03-21T15:17:54+00:00March 21st, 2025|Endpoints News|
Visen Pharmaceuticals prices $86M Hong Kong IPOnews2025-03-20T16:40:24+00:00March 20th, 2025|Endpoints News|
WuXi AppTec’s US revenue growth continues to dip in post-Biosecure environmentnews2025-03-17T18:34:26+00:00March 17th, 2025|Endpoints News|
Merck KGaA says earlier moves to localize manufacturing help ease Trump tariff impact news2025-03-06T15:26:35+00:00March 6th, 2025|Endpoints News|
China bans imports of Illumina’s DNA sequencers following US tariffsnews2025-03-04T20:24:53+00:00March 4th, 2025|Endpoints News|
